Genprex

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2009-01-01

Employees: 26

Market Cap: $1.8M

Website: http://www.genprex.com

Clinical Trials

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Phase 1

Recruiting

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Biological: quaratusugene ozeplasmid
Biological: atezolizumab

First Posted Date: 2023-01-30

Last Posted Date: 2024-05-20

Lead Sponsor: Genprex, Inc.

Target Recruit Count: 62

Registration Number: NCT05703971

Locations: 🇺🇸
Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States
🇺🇸
Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸
Northwest Cancer Specialists, P.C., Vancouver, Washington, United States

and more 6 locations

Quaratusugene Ozeplasmid (Reqorsa) in Combination with Pembrolizumab in Previously Treated Non-Small Lung Cancer

Phase 1

Active, not recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: quaratusugene ozeplasmid
Drug: docetaxel
Drug: pembrolizumab
Drug: ramucirumab
Drug: Investigator's Treatment of Choice

First Posted Date: 2021-09-30

Last Posted Date: 2024-10-01

Lead Sponsor: Genprex, Inc.

Target Recruit Count: 180

Registration Number: NCT05062980

Locations: 🇺🇸
Moffitt Cancer Center - Magnolia Campus, Tampa, Florida, United States
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸
Washington University School of Medicine - Siteman Cancer Center, St. Louis, Missouri, United States

and more 3 locations

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Phase 1

Recruiting

Conditions: Carcinoma, Non-Small Cell Lung

Interventions: Biological: quaratusugene ozeplasmid
Drug: Platinum-Based Chemotherapy
Drug: osimertinib

First Posted Date: 2020-07-27

Last Posted Date: 2024-10-17

Lead Sponsor: Genprex, Inc.

Target Recruit Count: 158

Registration Number: NCT04486833

Locations: 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
Carle Cancer Institute, Urbana, Illinois, United States
🇺🇸
Millennium Oncology, Houston, Texas, United States

and more 4 locations

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer

Interventions: Drug: Erlotinib
Drug: Dexamethasone
Drug: Diphenhydramine

First Posted Date: 2011-10-20

Last Posted Date: 2022-03-02

Lead Sponsor: Genprex, Inc.

Target Recruit Count: 25

Registration Number: NCT01455389

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy